The World Health Organization (WHO) and its COVAX partners are hosting a summit next week with governments and pharmaceutical companies to address the bottlenecks in COVID-19 vaccine production and delivery. This follows a spectacular start in the past week for COVAX, the global vaccine delivery platform, which delivered more than 20 million doses of COVID-19 […] Continue reading ->
The contribution COVID-19 vaccines can make to beating the pandemic will depend on the extent to which they are produced at scale, priced affordably, and deployed globally, says the first peer reviewed study on equitable access to vaccines, published in The Lancet on Friday.  The Lancet article comes in the wake of a joint appeal […] Continue reading ->
As global stocks of remdesivir, one of the few promising therapeutics for COVID-19, run low, the drug’s maker Gilead Sciences says that voluntary licensing to enable more manufacturers to produce the drug will not help expand access, countering advocates’ calls.  Rather, the lack of a “coordinated global supply chain” is to blame for worldwide shortages […] Continue reading ->
As the 73rd World Health Assembly approaches, the European Union-sponsored draft resolution on the COVID-19 response is gathering steam and storm as it rolls closer to the planned opening of the Assembly on 18 May – with far less clarity about how it might actually hit the shores of the public debate.  The resolution aims […] Continue reading ->
In the largest global collaboration to address the COVID-19 crisis so far, the World Health Organization, European Commission, and other partners including the Bill and Melinda Gates Foundation (BMGF), launched a new campaign to accelerate development of COVID-19 diagnostics, drugs, and vaccines – and just as critically ensure that they are affordable and accessible worldwide. […] Continue reading ->
“We all have a vested interest to stop this epidemic,” says Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). As WHO on Tuesday convenes a Global Research & Innovation Forum to rapidly ramp up R&D, Cueni spoke with Health Policy Watch  about what he describes as  “the extraordinary willingness […] Continue reading ->
Funding to develop new drugs for some of the world’s leading infectious disease killers, such as HIV/AIDS, TB and malaria, reached a record high of US $4 billion in 2018, with private sector investment driving much of the increase, according to the 2019 G-FINDER Report, which tracks such investments globally. However, investments in neglected tropical […] Continue reading ->
Criminal activity surrounding the manufacture, distribution and sale of falsified medicines is “on the rise” as a global health problem in many developing countries and in rich nations – especially online – but efforts to stem the growing health threat will require robust collective action by all stakeholders, a leading Novartis official warned Friday in […] Continue reading ->
The issues around access to medicines at affordable prices has galvanized civil society, the pharmaceutical industry, the research community, and politicians this year in oft-contentious debate that shows no sign of abating. A day-long session hosted by the Global Health Centre of Geneva’s Graduate Institute, and cosponsored by the Swiss Institute of Intellectual Property and […] Continue reading ->